Biopharmaceutical firm Palatin Technologies of Princeton, NJ, announced that it will begin multisite phase III trials next month for LeuTech, its radiopharmaceutical for infection imaging. LeuTech consists of a monoclonal antibody labeled with technetium
Biopharmaceutical firm Palatin Technologies of Princeton, NJ, announced that it will begin multisite phase III trials next month for LeuTech, its radiopharmaceutical for infection imaging. LeuTech consists of a monoclonal antibody labeled with technetium for imaging such infections as appendicitis and osteomyelitis. Palatin expects to complete phase III trials in the first part of 1999.
The firm is also working on peptide-based therapeutics and imaging agents such as PT5, a cancer therapeutic; PT11, an infection imaging agent based on the company's metal ion-induced distinctive array of structures (MIDAS) metallopeptide technology; and PT14, a therapeutic agent for sexual dysfunction.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).